US Pharm. 2010;35(8):58.
Several factors, particularly loss of brand exclusivity for Singulair, Advair, and Symbicort, are expected to shrink the overall asthma drug market from $13.4 billion to less than $12.9 billion between 2012 and 2019 in the United States, the United Kingdom, several European countries, and Japan, according to a report by Decision Resources, a research and advisory firm specializing in pharmaceutical and health care issues. Increased competition and more restrictive health care reimbursement policies are also expected to contribute to the decline. According to the report, the lack of a blockbuster drug will mean that over the next 10 years, the asthma drug market will be defined in part by the development of new formulations, new combinations, and new delivery devices.
